Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-096 manufacturers

Filters

None products found

pp-096

Injection

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
Comments
Indication: Mild or early Alzheimer’s disease in adult patients, targeting neurodegenerative progression and cognitive decline Clinical stage: Phase 2b clinical development (randomized, placebo-controlled trial in Europe) Modality: Immunomodulatory inorganic compound (aluminum-based vaccine adjuvant repurposed as therapeutic agent) Mechanism / Target: Modulation of innate immune response and microglial activity; peripheral immune stimulation believed to reduce neuroinflammation and pathological processes in the hippocampus Route / form: Subcutaneous injection; injectable aluminum oxyhydroxide suspension administered repeatedly Differentiation: Non-amyloid, non-tau disease-modifying strategy; repurposes a well-characterized vaccine adjuvant with established safety history; earlier clinical observations showed slower cognitive decline and reduced hippocampal atrophy compared with comparator arms; potentially lower cost and simpler manufacturing compared with monoclonal antibody therapies
Manufacturer #38927

Clinical-stage biotechnology company developing immunomodulatory therapies for neurodegenerative diseases, particularly Alzheimer’s disease. Focuses on repurposing known compounds with established safety to create disease-modifying treatments. Strategy centers on clinical validation and future global partnerships.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.